Understanding neurodegenerative disease brain anoxia
MSG
And neurodegenerative disease
There is a relatively new area of research for which the food industry, to
Date, has had no comment, contradiction or excuse. These are studies which link
MSG to neurodegenerative disease.
Discovery that MSG caused lesions in specific areas of the brains of
Laboratory animals and concomitant proliferation of neuroendocrine dysfunction
Came through interest in the brain. It was brain research that identified
Glutamic acid as a possible, probable, and now certain neurotransmitter,
Transmitting nerve impulses. Likewise, it was study of the brain that suggested
That a group of these neurotransmitters, specifically the excitatory amino
Acids (EAA), possess properties that very likely play an important role in the
brain anoxia
Development of certain neurodegenerative diseases(172, 229-236). Glutamic
Acid and aspartic acid are among the EAA that have great potential for
Involvement in neuro-degenerative disease.
At the present time, significant headway in the study of neurodegenerative
Disease is being made. Three EAA receptor subtypes that mediate
Excitotoxicity have been identified, drugs with anti-excitotoxic actions have
Been discovered, and evidence for the complicity of both exogenous and
Endogenous excitotoxins in neurodegenerative disorders has begun to unfold.
There now is substantial evidence for the involvement of each EAA receptor
Subtype in one or more human neurodegenerative syndrome,
And recent findings suggest that EAA receptors are sensitive mediators of
brain anoxia
Excitotoxicity at both ends of the age spectrum.(231)
All forms of MSG are exogenous sources of glutamic acid, i.E., coming from
Outside of the body. There are over 40 ingredients that contain MSG without
Giving consumers a clue to its presence. In addition, MSG can be produced when protease enzymes or reaction
Flavors are used in the manufacture of processed food. Processed free glutamic
Acid (MSG) always contains free glutamic acid, an EAA.
It has been suggested, and there is evidence to support the suggestion, that
The EAA might well play a role in the following neurodegenerative conditions:
Sulfite oxidase deficiency; epileptic, hypoglycemic
And hypoxic/ischemic brain damage; central nervous system trauma; dementia pugilistica; domoate dementia; olivopontocerebellar degeneration; neurolathyrism;
brain anoxia
Amyotrophic lateral sclerosis, parkinsonism, alzheimer’s dementia; huntington’s
Disease; and wernicke/ korsakoff
Syndrome(231). These conditions are referred to as part of the glutamate
Cascade.
The
Following excerpt from the march 15, 2004 american
Family physician illustrates the relationship between glutamate and
Alzheimer’s disease.
Memantine ( namenda)
For moderate to severe alzheimer’s disease
Adrienne Z. Ables, pharn.D .,
Spartanburg, south carolina
Synopsis:
Memantine ( namenda) is an
N-methyl-d-aspartate (NMDA) receptor blocker indicated for the treatment of
Moderate to severe alzheimer’s disease (AD). The NMDA receptor is activated
By glutamate, the primary excitatory neurotransmitter in the brain.Brain anoxia overstimulation
By glutamate may result in neuronal damage and has been implicated in
Neurodegenerative disorders such as AD. Memantine
Is the first pharmacologic agent approved by the U.S. Food and drug
Administration for the treatment of moderate to severe AD.
REFERENCES
172. Olney, J.W. Excitatory neurotoxins as food additives: an
Evaluation of risk. Neurotoxicology 2:
163-192, 1980.
229. Olney, J.W. Excitatory amino acids and neuropsychiatric
Disorders. Biol psychiatry 26: 505-525,
1989.
230. Choi, D.W., and rothman. S.M. The role of glutamate neurotoxicity
In hypoxic-ischemic neuronal death. Annu
Rev neurosci 13: 171-182, 1990.
231. Olney, J.W. Excitotoxic amino acids and neuropsychiatric
Disorders. Annu rev pharmacol toxicol 30: 47-71, 1990.Brain anoxia
232. Olney, J.W. Excitotoxicity: an overview. Biol
Psychiatry 27: 90A, 1990. (abstract)
233. Coyle, J.T. Glutamate receptors and age-related neurodegenerative
Disorders. Biol psychiatry 27: 91A,
1990.
234. Pomara, N., deptula,
D., singh, R., lewitt, P.A., and banay-schwartz,
M. Excitatory amino acid concentrations in CSF of patients with alzheimer’s
Disease. Biol psychiatry 27: 91A, 1990.
235. Zukin, S.R., and javitt,
D.C. The NMDA-PCP theory of schizophrenia: implications of receptor
Interactions. Biol psychiatry 27: 91A,
1990.
236. Olney, J.W. Excitotoxins and neurological diseases. Proceedings
Of the 11th international congress of neuropathology, kyoto, japan, september
2-8, 1990.